VISUAL-AF: Prevalence and Predictors of Esophageal Thermal Lesions in High-power-Short-duration Ablation of Atrial Fibrillation

Sponsor
Leipzig Heart Institute GmbH (Other)
Overall Status
Recruiting
CT.gov ID
NCT05709756
Collaborator
(none)
263
2
29
131.5
4.5

Study Details

Study Description

Brief Summary

Patients with documented atrial fibrillation who were referred to our clinic for catheter ablation will undergo standard HPSD ablation and subsequent esophagoscopy.

After esophagoscopy patients will be followed up for one month in the form of a telephone follow-up.

The primary endpoint of the study assessed by esophagoscopy performed on the day after the index catheter ablaton is the incidence of esophageal thermal lesions.

Secondary endpoints include:
  1. The size of the esophageal thermal lesions.

  2. The severity of esophageal thermal lesions.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    263 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Prevalence and Predictors of Esophageal Thermal Lesions in High-Power-Short-Duration Ablation of Atrial Fibrillation
    Actual Study Start Date :
    Mar 1, 2021
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Aug 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Prevalence of ablation-related esophageal thermal lesions [One day after Catheter ablation]

      It will be assessed by means of Esophagoscopy

    Secondary Outcome Measures

    1. Size of ablation-related esophageal thermal lesions [One day after Catheter ablation]

      It will be assessed by means of Esophagoscopy

    2. Severity of ablation-related esophageal thermal lesions [One day after Catheter ablation]

      It will be assessed by means of Esophagoscopy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Atrial fibrillation documented in the 12-lead ECG

    • Indication for catheter ablation in accordance with currentn ESC guidelines

    Exclusion Criteria:
    • Pregnancy

    • Women of childbearing potential without a negative pregnancy test within 48 hours prior to ablation procedure

    • Known intracardiac or other thrombi

    • Contraindication to anticoagulation

    • Contraindication to esophagoscopy: diseases and deformities of the cervical spine, esophageal varices

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Arash Arya Leipzig Saxony Germany 04289
    2 Department of Electrophysiology, Leipzig Heart Center at University of Leipzig Leipzig Saxony Germany 04289

    Sponsors and Collaborators

    • Leipzig Heart Institute GmbH

    Investigators

    • Study Chair: Gerhard Hindricks, MD, Leipzig Heart Center at University of Leipzig
    • Study Director: Arash Arya, MD, Leipzig Heart Center at University of Leipzig

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Leipzig Heart Institute GmbH
    ClinicalTrials.gov Identifier:
    NCT05709756
    Other Study ID Numbers:
    • 549/20-ek
    First Posted:
    Feb 2, 2023
    Last Update Posted:
    Feb 2, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Leipzig Heart Institute GmbH
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 2, 2023